Autolus Therapeutics plc (AUTL)
NASDAQ: AUTL · Real-Time Price · USD
1.370
-0.020 (-1.44%)
At close: Nov 26, 2025, 4:00 PM EST
1.360
-0.010 (-0.73%)
After-hours: Nov 26, 2025, 7:59 PM EST
Autolus Therapeutics Revenue
Autolus Therapeutics had revenue of $21.19M in the quarter ending September 30, 2025. This brings the company's revenue in the last twelve months to $51.13M, up 406.67% year-over-year. In the year 2024, Autolus Therapeutics had annual revenue of $10.12M with 496.00% growth.
Revenue (ttm)
$51.13M
Revenue Growth
+406.67%
P/S Ratio
7.13
Revenue / Employee
$78,658
Employees
650
Market Cap
364.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10.12M | 8.42M | 496.00% |
| Dec 31, 2023 | 1.70M | -4.66M | -73.30% |
| Dec 31, 2022 | 6.36M | 4.03M | 172.96% |
| Dec 31, 2021 | 2.33M | 615.00K | 35.86% |
| Dec 31, 2020 | 1.72M | -1.19M | -41.02% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AUTL News
- 1 day ago - Why Is Autolus Therapeutics Stock Trading Higher On Tuesday? - Benzinga
- 1 day ago - NICE Recommends AUCATZYL® (obecabtagene autoleucel) as a Treatment Option for Adult Patients (≥26 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)¹ - GlobeNewsWire
- 12 days ago - Autolus Therapeutics: Trading At Cash Is Not Justified With This Pipeline - Seeking Alpha
- 13 days ago - Autolus Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - GlobeNewsWire
- 14 days ago - Autolus Therapeutics plc (AUTL) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Autolus Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates - GlobeNewsWire
- 23 days ago - Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2025 - GlobeNewsWire
- 27 days ago - Autolus Therapeutics to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025 - GlobeNewsWire